ImpediMed

[ImPoster]

It's been a rocky road and a long slide from $0.90 five years ago to $0.09 today so thought it was time to revisit this company. As far as I am aware, no new technologies have stepped up to address the issue of lymphedema, the company's major focus and strongest path toward profitability.

I've updated the iBox to reflect what I believe the current status of the company to be. They appear to have cut way back on the burn rate but still face the two major challenges of gaining coverage from health insurance companies and upgrading their CPT status which would have a positive impact on such coverage, reimbursement and payment to physicians offering the test to their patients. A breakthrough in either or both 'impediments' could have a very positive impact on the current share price.